1. Scrip
  2. >>Focus On Asia
  3. >>China

US/China-based MicuRx Gets $55m Series C Funding For MRX-I Antibiotic

 
• By Sten Stovall

Hayward, California-based antibiotics developer MicuRx Pharmaceuticals raised $55 million in a Series C venture capital round to fund further clinical trials in the US for its next-generation oral oxazolidinone MRX-I through to the drug’s first New Drug Application filing in China.

US-Money-and-Pills_V2_1200x675

MicuRx Pharmaceuticals Inc.’s latest financing exercise – a Series C financing - brought it $55m which the Sino-US drug developer will use to progress its lead drug candidate, MRX-I, an oral oxazolidinone antibiotic currently in Phase III China trials.

MicuRx touts MRX-I’s oral availability and safety profile as advantages over the other drugs. MRX-I is designed to treat infections caused by Gram-positive, multidrug-resistant bacteria such as methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE), with better tolerability and safety profile compared to current oxazolidinone agents

More from China

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.